Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …
Metabotropic glutamate receptors and neurodegenerative diseases
Glutamate is the most important excitatory neurotransmitter of the mammalian central
nervous system (CNS), playing an important role in memory, synaptic plasticity and neuronal …
nervous system (CNS), playing an important role in memory, synaptic plasticity and neuronal …
Role of mitogen activated protein kinase signaling in Parkinson's disease
Parkinson's disease (PD) is a neurodegenerative disorder caused by insufficient dopamine
production due to the loss of 50% to 70% of dopaminergic neurons. A shortage of dopamine …
production due to the loss of 50% to 70% of dopaminergic neurons. A shortage of dopamine …
Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease
MA Cenci, K Skovgård, P Odin - Neuropharmacology, 2022 - Elsevier
Dopamine replacement therapy with l-DOPA is the most efficacious symptomatic treatment
for Parkinson's disease, but its utility is limited by a development of motor fluctuations and …
for Parkinson's disease, but its utility is limited by a development of motor fluctuations and …
Continuous dopaminergic stimulation as a treatment for Parkinson's disease: current status and future opportunities
Levodopa‐induced motor complications remain an important source of disability for many
patients with Parkinson's disease. Substantial laboratory evidence indicates that motor …
patients with Parkinson's disease. Substantial laboratory evidence indicates that motor …
Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy
C Alcacer, L Andreoli, I Sebastianutto… - The Journal of …, 2017 - Am Soc Clin Investig
Parkinson's disease (PD) patients experience loss of normal motor function (hypokinesia),
but can develop uncontrollable movements known as dyskinesia upon treatment with L …
but can develop uncontrollable movements known as dyskinesia upon treatment with L …
Molecular mechanisms and therapeutic strategies for levodopa-induced dyskinesia in Parkinson's disease: a perspective through preclinical and clinical evidence
R Bandopadhyay, N Mishra, R Rana, G Kaur… - Frontiers in …, 2022 - frontiersin.org
Parkinson's disease (PD) is the second leading neurodegenerative disease that is
characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been …
characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been …
The signaling and pharmacology of the dopamine D1 receptor
J Jones-Tabah, H Mohammad, EG Paulus… - Frontiers in Cellular …, 2022 - frontiersin.org
The dopamine D1 receptor (D1R) is a Gαs/olf-coupled GPCR that is expressed in the
midbrain and forebrain, regulating motor behavior, reward, motivational states, and cognitive …
midbrain and forebrain, regulating motor behavior, reward, motivational states, and cognitive …
Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease
H You, LL Mariani, G Mangone… - Cell and tissue …, 2018 - Springer
There is currently no cure for Parkinson's disease. The symptomatic therapeutic strategy
essentially relies on dopamine replacement whose efficacy was demonstrated more than 50 …
essentially relies on dopamine replacement whose efficacy was demonstrated more than 50 …
mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia
I Sebastianutto, MA Cenci - Current Opinion in Pharmacology, 2018 - Elsevier
Highlights•Targeting specific mGluRs normalizes excessive glutamate/GABA transmission in
PD and LID models.•mGluR5 NAMs normalise biochemical and molecular changes …
PD and LID models.•mGluR5 NAMs normalise biochemical and molecular changes …